	US 12,472,241 B2
	Treatment of respiratory disorders with arachidonate 15-lipoxygenase (ALOX15) inhibitors
Julie Horowitz, Tarrytown, NY (US); and Aris Baras, Tarrytown, NY (US)
Assigned to Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US)
Filed by Regeneron Pharmaceuticals, Inc., Tarrytown, NY (US)
Filed on Dec. 23, 2019, as Appl. No. 16/725,309.
Claims priority of provisional application 62/785,899, filed on Dec. 28, 2018.
Prior Publication US 2020/0254070 A1, Aug. 13, 2020
Int. Cl. A61P 11/02 (2006.01); A61K 38/46 (2006.01); C12N 15/113 (2010.01); G01N 33/68 (2006.01)

CPC A61K 38/465 (2013.01) [A61P 11/02 (2018.01); C12N 15/1137 (2013.01); G01N 33/6815 (2013.01); G01N 33/6818 (2013.01)]

7 Claims

1. A method of treating a patient having a nasal polyp, allergic rhinitis, asthma, and/or aspirin-exacerbated respiratory disease (AERD), the method comprising administering an Arachidonate 15-Lipoxygenase (ALOX15) inhibitor to the patient,

wherein the ALOX15 inhibitor comprises an ALOX15 antisense molecule;

wherein the patient is heterozygous or reference for ALOX15 Thr560Met; and

wherein the patient is reference for ALOX15, Leu651fs, Asn658Lys, Val474Ala, and/or Leu106fs.